In this roundtable discussion published in Corporate Disputes, Sean Sheridan and two other panelists discuss recent trends in patent disputes. Dr. Sheridan dicusses the sharp decline in petitions for inter partes review filed at the Patent Trial and Appeal Board (PTAB) as well an an increase in the number of bills seeking to limit patent protection for pharmaceutical and biologic products.
Click the link below to download a PDF of the article.
CRA consultants named top IP strategists in IAM Strategy 300 2021
Robert Goldman, Daniel McGavock, Dr. Richard Razgaitis, and Larry Rosenberg were recognized in the latest edition of IAM Strategy 300 – The World’s Leading IP...